Bone turnover makers; economic impact; medication adherence; treatment response; Biomarkers; Humans; Economics, Medical; Medication Adherence/statistics & numerical data; Bone Remodeling/drug effects; Bone Remodeling; Health Policy; Pharmacology (medical)
Disciplines :
Public health, health care sciences & services
Author, co-author :
Li, Nannan ; Department of Health Services Research, Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands ; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
Jørgensen, Niklas Rye; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark ; Institute of Clinical Medicine, Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique
Hiligsmann, Mickaël ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Department of Health Services Research, Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands ; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
Language :
English
Title :
The impact of bone turnover marker on medication adherence and the health economics-related consequences.
Publication date :
September 2024
Journal title :
Expert Review of Pharmacoeconomics and Outcomes Research
Kanis JA, Cooper C, Rizzoli R, et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int. 2019Mar;104(3):235–238.
Rabenda V, Reginster JY., Overcoming problems with adherence to osteoporosis medication. Expert Rev Pharmacoecon Outcomes Res. 2010Dec;10(6):677–689. doi: 10.1586/erp.10.76
Fatoye F, Smith P, Gebrye T, et al. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019Apr14;9(4):e027049. doi: 10.1136/bmjopen-2018-027049
Koller G, Goetz V, Vandermeer B, et al. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporosis Int. 2020Nov;31(11):2093–2102.
Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int. 2010Mar;86(3):202–210. doi: 10.1007/s00223-009-9329-4
Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013Jan;24(1):23–57.
Fontalis A, Eastell R., The challenge of long-term adherence: the role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone. 2020Jul1;136. doi: 10.1016/j.bone.2020.115336
Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis Int. 2011Feb;22(2):391–420. doi: 10.1007/s00198-010-1501-1
Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004Mar;89(3):1117–1123. doi: 10.1210/jc.2003-030501
International Osteoporosis Foundation and European Calcified Tissue Society Working Group, Diez-Perez A, Naylor KE, et al. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017Mar1;28(3):767–774. doi: 10.1007/s00198-017-3906-6
Hiligsmann M, Salas M, Hughes DA, et al. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR medication adherence & persistence special interest group. Osteoporosis Int. 2013Dec;24(12):2907–2918.
Migliorini F, Maffulli N, Spiezia F, et al. Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res. 2021May18;16(1):318. doi: 10.1186/s13018-021-02474-7
Migliorini F, Maffulli N, Spiezia F, et al. Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res. 2021May31;16(1):351. doi: 10.1186/s13018-021-02497-0
Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. Osteoporosis Int. 2012Dec;23(12):2769–2774.
Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92(4):1296–1304. doi: 10.1210/jc.2006-1526
Mattia L, Davis S, Mark-Wagstaff C, et al. Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and osteoporosis in Sheffield evaluation). Bone. 2022May1;158. doi: 10.1016/j.bone.2022.116347
Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012May;73(5):691–705.
Silverman SL, Nasser K, Nattrass S, et al. Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial. Osteoporosis Int. 2012Mar;23(3):1069–1074. doi: 10.1007/s00198-011-1721-z
Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2019May1;104(5):1595–1622. doi: 10.1210/jc.2019-00221
Lorentzon M, Branco J, Brandi ML, et al. Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther. 2019;36(10):2811–2824.
Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract.2020May;26(Suppl 1):1–46.
Lane NE, Saag K, O’neill TJ, et al. Real-world bone turnover marker use: impact on treatment decisions and fracture. Intern Osteoporosis. 2021May;32(5):831–840. doi: 10.1007/s00198-020-05734-0
Paskins Z, Moult A, Corp N, et al. Research priorities regarding the use of bisphosphonates for osteoporosis: a UK priority setting exercise. Osteoporosis Int. 2023Oct1;34(10):1711–1718. doi: 10.1007/s00198-023-06806-7
